PsylenciaMedia

Healing From the Inside Out: Bénédicte Mannix on Psilocybin & Mental Homeostasis

In this episode of Inside the Revival on Healthcare NOW Radio, host Jim Tate sits with Bénédicte ("Ben") Mannix - holistic psilocybin therapist, 'sophrotherapist', and founder of Sophrodelic in Kingston, Jamaica - for a candid and illuminating conversation about what truly personalized psychedelic-assisted therapy looks and feels like in practice. Ben has spent more than 30 years exploring psychedelics and over 15 years facilitating psilocybin sessions for clients across the globe. Her Sophrodelic protocol integrates Rogerian therapy, Sophrology, transgenerational therapy, and harm reduction into a framework she calls the pursuit of "mental homeostasis" - the capacity to return to alignment no matter what life throws your way. Against a landscape crowded with high-volume group retreat centers, Ben deliberately works one-on-one, valuing depth over scale, and treating each session as an individualized act of teaching rather than a wellness transaction. Jim and Ben explore the four-step Sophrodelic protocol (connection, pre-session, session, and integration), the science of the post-psilocybin neuroplasticity window, how dosing decisions are made collaboratively with clients, and why Ben sees psilocybin not as a medicine or a cure but as a tool - one that empowers the client, not the facilitator, as the true healer. They also discuss transgenerational trauma, the legal landscape in Jamaica, and why integration - not the journey itself - is the most critical determinant of lasting change.

Clearing the Plaque with Adam Butler

The DMT Field Guide with Author Adam Butler and Host Jim Tate

The People's Mushroom with Anna Ross, PhD

S1E15: TITLE: The People's Mushroom: Psychedelics, Policy, and the Push to Reclaim Scotland's Indigenous Apothecary with Anna Ross, PhD Join host Jim Tate travels north of the border to speak with Dr. Anna Ross, lecturer at the University of Edinburgh, co-founder of the Scottish Psychedelic Research Group (SPRG), and self-described "lived and living experience researcher" who came up through Scotland's 1990s rave scene. Dr. Ross traces the founding of SPRG, Scotland's rich but under-documented relationship with indigenous psychoactive plants, the conspicuous absence of clinical psychedelic trials north of England, the thorny politics of Compass Pathways and IP enclosure in the psychedelic space, and the underground scene that has quietly thrived for decades. She also opens up about her own encounters with DMT and her ongoing research focus: ontological shock, the profound and sometimes destabilizing worldview ruptures that psychedelics can produce, and which mainstream psychiatry still struggles to name, let alone treat. A rich, candid, and highly informed conversation from the northern edge of the psychedelic renaissance.

Extended-State DMT (DMTx) Method

S1E14: Extended-State DMT (DMTx) Method Join host Jim Tate and his guest Daniel McQueen, a professional psychedelic therapist and executive director of the Center for Medicinal Mindfulness, a psychedelic harm-reduction program and international psychedelic therapy training program focusing on Cannabis-Assisted Psychedelic Therapy and Cannabis-Assisted Psychotherapy. McQueen discusses his journey from underground guide to regulated access work in Colorado, his experiments extending DMT experiences via infusion, his views on psilocybin regulation, and the tensions inherent in commodifying sacred medicines.

Sacred Healing or Clinical Care?

S1E13: Sacred Healing or Clinical Care? Join host Jim Tate and his guest Justin Townsend, Founder and CEO of Myco Meditations, a leading psilocybin-assisted retreat organization based in Jamaica. Together, they explore the emerging role of psychedelics at the intersection of clinical treatment, sacred ceremony, and cultural transformation. From 6,000+ psilocybin journeys hosted in safe, structured retreats to debates over natural vs. synthetic psilocybin, Townsend sheds light on lessons learned, harm reduction practices, and the risks of unchecked commercialization in the US.